Affimed raises €20M to fund innovative antibody trials

With its lead antibody program poised to go into the clinic later this year and two more therapies expected to follow in 2011, Germany's Affimed Therapeutics AG has raised 20 million euros in a Series C. Affimed CEO Dr. Rolf H. Günther said that the money will fuel the work needed to produce data on its two top development programs. "This financing will also provide us with an excellent basis to support further development of our therapeutic pipeline and strengthen our position in...